Theravance Biopharma Stock News

Price T Rowe Associates Inc. MD trimmed its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 5.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,837 shares of the biopharmaceutical companys stock after selling 1,937 shares during the quarter. Price T Rowe Associates Inc. []

Theravance Biopharma, Inc. (NASDAQ:TBPH) has earned an average rating of Hold from the nine ratings firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective []

DUBLIN, Nov. 18, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medic

Full story available on Benzinga.com

Theravance Biopharma Inc (NASDAQ: TBPH) has voluntarily discontinued its Phase 2 study of izencitinib (gut-selective oral pan-JAK inhibitor) in Crohn's disease (Study 0173).  The decision follows

Equities analysts expect Theravance Biopharma, Inc. (NASDAQ:TBPH) to post earnings per share (EPS) of ($0.40) for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Theravance Biopharmas earnings. The lowest EPS estimate is ($1.02) and the highest is ($0.13). Theravance Biopharma posted earnings of ($0.92) per share during the same quarter last []

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q3 2021 Results - Earnings Call Transcript

DUBLIN, Oct. 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), will report its third quarter 2021 financial results and provide a business update after market close on Wednesday, Nov

The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street anal

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%.

The biotech is not enjoying a winning streak with its pipeline drugs.

The stock price of Theravance Biopharma Inc (NASDAQ: TBPH) decreased by over 19% pre-market. This is why it happened.

Theravance Biopharma Inc (NASDAQ: TBPH) will reduce its headcount by approximately 75% (estimated 270 positions), with most of the lay off to complete in November and the remainder in February 2022

Theravance Biopharma Inc. shares TBPH, -6.73% slid 34% in premarket trade Wednesday, after the company announced a major overhaul of its business including reducing its headcount by about 75%, or 270